Targeting-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

Julien Fleurence 1 Sophie Fougeray 1 Meriem Bahri 1 Denis Cochonneau 2 Béatrice Clémenceau 3 François Paris 1 Andras Heczey 4 Stéphane Birklé 1, *
* Corresponding author
1 CRCINA - Département ONCO - Equipe 14 - Endothelium radiobiology and targeting
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
2 CRCINA - Département ONCO - Equipe 9 - Apoptosis and tumor progression -ATP
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
3 CRCINA - Département INCIT - Equipe 1 - Immunobiology of Human αβ and γδ T cells and Immunotherapeutic Applications
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
Abstract : Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included.
Document type :
Journal articles
Complete list of metadatas

Cited literature [144 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01474322
Contributor : Elizabeth Bernardo <>
Submitted on : Wednesday, February 22, 2017 - 4:34:24 PM
Last modification on : Monday, May 20, 2019 - 3:32:02 PM
Long-term archiving on : Tuesday, May 23, 2017 - 2:31:33 PM

File

ArticleBirkleEq14.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, et al.. Targeting-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. Journal of Immunology Research, Hindawi Publishing Corporation, 2017, 2017, [Epub ahead of print]. ⟨10.1182/blood-2013-11-541235⟩. ⟨inserm-01474322⟩

Share

Metrics

Record views

211

Files downloads

262